Intensive combined-modality therapy in small cell lung cancer.
Thatcher, Nick Lorigan, Paul C Burt, Paul A Stout, Ronald
Thatcher, Nick
Lorigan, Paul C
Burt, Paul A
Stout, Ronald
Citations
Altmetric:
Abstract
Combination ifosfamide/carboplatin/etoposide (ICE) chemotherapy and ICE plus mid-cycle vincristine (VICE) are reviewed. Thoracic radiotherapy and prophylactic cranial irradiation given as single fractions in the majority of patients have been intercalated with VICE in the later studies. The patient populations have not been intensively staged with computed tomography, etc, but do have reasonable Karnofsky performance status ratings and biochemical screens. A policy of no dose reduction over six courses of VICE chemotherapy has been followed in three consecutive studies of 166 patients. The minimum length of follow-up is 26 months and the 2-year survival rate is > or = 30%. Hematopoietic growth factor support in an attempt to overcome the considerable myelosuppression with VICE therapy is currently being evaluated.
Description
Date
1994-06
Publisher
Collections
Keywords
Lung Cancer
Type
Article
Citation
Intensive combined-modality therapy in small cell lung cancer. 1994, 21 (3 Suppl 6):9-22 Semin. Oncol.